![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Plc Systems, | AMEX:PLC | AMEX | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
RNS Number:2151J Pall Corporation 26 March 2003 Major Blood Centers Select Pall Bacteria Detection System "BDS" To Curb Blood Transfusion Fatalities East Hills, NY (03/24/2003) - - Two of the nation's major blood centers, Blood Centers of the Pacific and Indiana Blood Center adopt the Pall BDS to detect bacterial contamination of platelets, the leading infectious cause of transfusion-related fatalities. The Pall BDS, developed by Pall Corporation (NYSE: PLL) tests for the presence of bacteria. It is the only system with FDA clearance to detect bacteria in all platelets, whether derived from single donor (apheresis) or whole blood collection procedures. Blood Centers of the Pacific (a subsidiary of Blood Systems Inc., the second largest blood collection organization in the U.S.) is a nonprofit community based organization that provides blood components to hospitals, physicians and patients throughout Northern California. Indiana Blood Center is one of the nation's largest independent blood banking institutions providing blood products to more than forty-six member hospitals throughout Central and Southern Indiana. It also provides centralized testing services to many centers in the eastern half of the U.S. "These centers deserve praise for adopting the latest technology to reduce the serious risk of septic complications and fatalities posed by contaminated platelets," said Roberto Perez, President of Pall Medical. "Their use of this technology demonstrates their commitment and leadership to improve the safety of the nation's blood supply." The issue of bacterial contamination of blood is in the spotlight as a transfusion safety priority since technology is now available that can address the problem. On February 6, 2003, the Blood Safety and Availability Committee of the U.S. Department of Health and Human Services (HHS) issued a recommendation for "expedited implementation of available measures to reduce the risk of bacterial contamination in platelets." This was echoed by both the College of American Pathologists and the American Association of Blood Banks (the professional association of the blood banking and transfusion medicine community), which also announced new standards to implement no later than March 1, 2004 methods to test for the presence of bacteria in all platelet components. It is anticipated that the HHS recommendation and the new standards will accelerate adoption of the Pall BDS by blood centers nationwide. "The Pall BDS gives us a unique and cost-effective way to address the long- standing problem of bacterial contamination of platelets. With this new system, we will be able to test apheresis platelet samples and detect bacterial contamination right in our blood center, thus ensuring a safer product for patients," said Dan Waxman, M.D., Executive Vice President and Chief Medical Director of Indiana Blood Center. "Since our center operates in a decentralized manner with multiple processing and distribution sites, the Pall BDS, enables us to test platelets for bacterial contamination in our operating environment. We'll have the results before the platelets are shipped, thus improving the safety of transfusions," said Nora Hirschler, M.D., President and CEO of Blood Centers of the Pacific. Platelets, a blood component required for clotting are most often given to immunocompromised patients as a life-saving treatment for cancer, leukemia and other blood disorders. Approximately 2.1 million platelets are transfused each year in the U.S. Platelets are the blood component most vulnerable to bacterial contamination because they must be stored at room temperature, which facilitates bacterial growth. It is estimated that the bacterial contamination rate is anywhere from one in 2,000 to one in 3,000, and the prevalence of severe episodes of transfusion-associated sepsis is probably on the order of 1:50,000 platelet transfusions. Studies have shown that the Pall BDS detects the strains of bacteria reported to cause more than 98 percent of the fatalities resulting from the transfusion of contaminated platelets. The Pall BDS accurately detects both gram-positive and gram-negative bacteria. The system can be easily incorporated into the blood banking process with minimal cost, time and technician training. About Pall Corporation Pall Corporation is the global leader in the rapidly growing field of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceuticals, transfusion medicine, semiconductors, municipal drinking water and aerospace. Pall Medical, part of the Company's Life Sciences segment, is the worldwide leader in leukocyte reduction filtration technologies for both red blood cells and platelets. The Company is involved in extensive research and development in many areas of blood safety. Total revenues for fiscal 2002 were about $1.3 billion. The Company is headquartered in East Hills, New York, and has operations in more than 30 countries. Further information can be found on its Web site http://www.pall.com. For More Information: Patrice Radowitz, Media Inquiries (516) 801-9104 or email: Patrice_Radowitz@pall.com Diane Foster, Investor Relations Inquiries (516) 801-9848 or email: Diane_Foster@pall.com This information is provided by RNS The company news service from the London Stock Exchange END RESUNURRONROUAR
1 Year P L C Systems Chart |
1 Month P L C Systems Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions